...
首页> 外文期刊>Revista de la Sociedad Espanola del Dolor >Efectividad, tolerabilidad y calidad de vida en el tratamiento del dolor crónico no oncológico, con tramadol de liberación controlada en dosis única diaria
【24h】

Efectividad, tolerabilidad y calidad de vida en el tratamiento del dolor crónico no oncológico, con tramadol de liberación controlada en dosis única diaria

机译:每日一次控释曲马多治疗慢性非癌性疼痛的有效性,耐受性和生活质量

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: To assess the effectiveness and tolerability of the management of chronic pain unrelated to cancer with controlled and sustained-release tramadol administered in a single daily dose. Material and methods: Prospective, observational, multicentric pharmacoepidemiological study. A total of 100 Pain Units in our country were involved. Patients with chronic pain unrelated to cancer that had initiated treatment with sustained and controlled-release tramadol were included. In order to assess the effectiveness of the drug, anthropometric characteristics, type of pain, severity and effect on sleep and quality of life were recorded. Two follow-up visits were performed at one week and at one month after the beginning of the treatment and variations in the following pain scores were recorded: visual analogical scale and Lattinen test, quality of life, side effects and changes in the treatment. Results: Nine hundred and seven patients, 66.03% women and 33.97% men were included in the study. Of these, 52.92% had lumbalgia and 33,96% osteoarthritis. A significant decrease in all the pain scores was observed since the first week of treatment. The incidence of side effects was 16.8%, with a mean length of 6.3 ± 4 days. Nausea and vomiting were the side effects with the highest incidence (18.3%), followed by constipation and somnolence (10.5 and 10.3%, respectively). The highest impact of the analgesic response to controlled and sustained-release tramadol was seen in the physical condition score of the quality of life. Treatment compliance was adequate in 93.22% of the patients, while 66.38% reported satisfaction or high satisfaction with the treatment at the end of the study. Conclusions: Controlled and sustained-release tramadol was highly effective for the relief of pain since the first week of treatment. Tolerability was good, with a low rate of mild side effects. Nausea and vomiting were the side effects with the highest incidence.
机译:目的:评估每日一次剂量控制和缓释曲马多治疗与癌症无关的慢性疼痛的有效性和耐受性。材料和方法:前瞻性,观察性,多中心药物流行病学研究。我们国家总共涉及100个疼痛单位。包括已开始接受持续和控释曲马多治疗的与癌症无关的慢性疼痛患者。为了评估药物的有效性,记录了人体测量学特征,疼痛类型,严重程度以及对睡眠和生活质量的影响。在治疗开始后的一周和一个月进行两次随访,并记录以下疼痛评分的变化:视觉类比量表和Lattinen测试,生活质量,副作用和治疗变化。结果:该研究共纳入907例患者,其中女性占66.03%,男性占33.97%。其中,有52.92%的人有腰痛和33.96%的骨关节炎。自治疗第一周以来,所有疼痛评分均明显降低。副作用发生率为16.8%,平均时长为6.3±4天。恶心和呕吐是发生率最高的副作用(18.3%),其次是便秘和嗜睡(分别为10.5%和10.3%)。对生活质量的身体状况评分显示,对控释和缓释曲马多的镇痛反应影响最大。在研究结束时,93.22%的患者的治疗依从性足够,而66.38%的患者对治疗表示满意或高度满意。结论:自治疗第一周以来,控释和缓释曲马多对缓解疼痛非常有效。耐受性良好,轻度副作用率低。恶心和呕吐是发生率最高的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号